Publicacions

Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study

Pérez-Lamas L, Segura Diaz A, García Delgado R, Álvarez-Larrán A, Senin MA, Mora E, Fox ML, Pastor Galan I, Azaceta G, Garrido Paniagua S, Pérez Lopez R, Trejos Carvajal DM, Angona A, Albo López C, Lorente Alegre P, Vara M, Vera Goñi JA, De Miguel Llorente D, Fernández Rodríguez Á, Marín Sanchez A, Hernando Megido A, Gómez Casares MT, Stuckey R, Carreño-Tarragona G, De Las Heras Rodriguez N, Xicoy B, Pérez Encinas M, Mata Serna R, Núñez Martin-Buitrago L, Ferrer Marín F, Amer Salas N, Guillén Rienda C, Velez P, Lamarca Eraso L, Martín S, Luts Khoroz I, De Cabo López E, Gil A, Martín-Consuegra Ramos S, Marco De Lucas F, Otero Martinez-Fornes MJ, Martín Mateos ML, Arquero T, Cabezudo Pérez E, López Gómez LA, Martínez Hellin Á, Tejedor A, Herrera de Pablo E, Mata Vazquez MI, Castillo Valero I, Fernández MJ, Aguilar C, Santaliestra M, García Menchon A, Navas Elorza B, Duran MA, Pérez Sala M, Hernández Santamaría T, Muñoz Jarreño MÁ, Dávila-Valls J, Torres Jiménez W, Gonzálvez Fernández JA, Torres Mantilla HA, Cobo Rodríguez T, Abuin Blanco A, Pérez F, Osorio Prendes S, Beneit Villena P, Peralta R, Herrera F, Cañamero Giro E, Jiménez Bárcenas R, Gasior Kabat M, González De Villambrosia S, Tercero-Mora Rodriguez MT, Menéndez Cuevas M, Cuevas Ruiz B, Fonseca-Santos M, Garcés Piquer S, De La Puerta R, Lorenzo Vizcaya Á, Hernández Boluda JC, García Gutiérrez V.

Blood Cancer J

Competing interests: LPL: Novartis, Incyte and GSK; travel grants. GSK and Novartis speaker honoraria. AAL: honoraria fees for participating in advisory board from AOP and for lectures from Novartis and GSK. RJB: Novartis, GSK; speaker honoraria. VGG: Novartis; BMS; Incyte; Pfizer and GSK; travel grants, research funding, advisory board. ASD: Novartis; BMS; Incyte and Pfizer; travel grants. Novartis; research funding, advisory board. JCHB: advisory honoraria from Incyte, GSK, Novartis, Pfizer, BMS, and AOP Health; travel support from Incyte and Pfizer; speaker fees from GSK, Novartis, Pfizer, and Incyte. Ethics approval and consent to participate: The study received approval from the Ramón y Cajal Hospital Ethics Committee (code number 176/24) and the GEMFIN Scientific Committee, and adhered to ethical standards for medical research involving human subjects. The study was conducted in accordance with the Declaration of Helsinki and other relevant guidelines and regulations. Written informed consent was obtained from all participants.

Obre a Pubmed